Comparison of Xanthine Oxidase Inhibitors in Gouty Patients with Hyperuricemia

Objective: Febuxostat is more effective/superior to Allopurinol in reducing the serum uric acid (SUA) level in the treatment of hyperuricemic with gout. Methods: This randomized control study included 200 hyperuricemic patients with gout, at Multi-center study including Outdoor Departments of Medicine from four different hospitals of Lahore, Pakistan. Patients age range 18-50 years diagnosis with hyperuricemia and gout, SUA >8 mg/dl were included while severe renal impairment and alanine aminotransferase and aspartate aminotransferase patients were excluded from the study. Results: About 200 patients treated with hyperuricemic with gout were randomly divided into four groups (50%) patients were in each group received different treatment. Out of 200 patients, 118 (59%) were male and 82 (41%) were female with mean age 42.37±9.47 years. Among the Febuxostat group, patients’ success rate of lowering SUA level was found to be 32 (64%) as compared to Allopurinol 16 (32%). Drug compliance was similar among treatment groups, i.e. Allopurinol and Febuxostat while the trend toward drug compliance in Allopurinol + Vitamin C and Febuxostat + Vitamin C groups showed similar in number. Conclusion: Febuxostat is safe and effective to Allopurinol for the treatment of hyperuricemia with gout as the Febuxostat has a significant association with lowering SUA concentration <6 mg/dl. It is concluded that although Febuxostat is safe and effect alone in gouty patients, but it has somehow a little effect with Vitamin C especially in patients who are feeble.